Scientists reported signs of intestinal diseases ten years before diagnosis
Changes in the immune system may indicate the development of Crohn's disease and ulcerative colitis ten years before diagnosis. An international team of scientists has discovered characteristic combinations of antibodies in blood samples from people who were subsequently diagnosed with these diseases. How a blood test can help assess the risk of inflammatory bowel diseases and what prevents this approach from being applied in clinical practice — in the Izvestia article.
What happens before the diagnosis appears
Crohn's disease and ulcerative colitis are inflammatory bowel diseases. These are chronic conditions in which immune response disorders contribute to prolonged inflammation and damage to the digestive tract. Despite belonging to the same group, the diseases differ in the nature of the lesion and the features of the course.
The authors of the new work decided to trace this process using blood samples collected long before the disease was detected. They were interested in whether the immune responses of future patients differ from those of healthy people and whether these differences can be used to predict not only the development of the disease, but also its subsequent course.
The scientists paid special attention to antibodies, proteins of the immune system that recognize certain molecular structures. The combination of antibody reactions makes it possible to investigate which targets the immune response is directed at and how it changes over time.
It's about looking for early signs of risk. The discovery of differences in old blood samples does not mean that researchers have established the exact moment of the onset of the disease or have received a ready-made way to prevent it.
How scientists studied changes in blood
Experts analyzed 2,000 blood serum samples from 500 people. 200 participants were subsequently diagnosed with Crohn's disease, and another 200 with ulcerative colitis. The control group included 100 healthy people, comparable to future patients in age and gender.
The samples were collected at several periods: at the time of diagnosis, as well as approximately two, four and ten years before it. Thanks to this, scientists were able to compare immune responses at different stages, rather than being limited to differences between already ill and healthy participants.
A scientific publication in the Gut journal clarifies that the material was obtained from a research cohort of US military personnel. PhIP-Seq technology was used for the analysis, which makes it possible to simultaneously study a large number of antibody reactions. The test covered about 357,000 protein fragments related to microorganisms, viruses, food, and the immune system.
This scale allowed us to look for combinations of immune changes. A separate reaction could occur in different people, while the combination of signs gave a more detailed picture of the state of the immune system before the development of the disease.
A comparison of the samples showed that characteristic differences between future patients and the control group could be detected as early as ten years before diagnosis. At the same time, Crohn's disease and ulcerative colitis revealed both common features and their own combinations of reactions.
What signs preceded Crohn's disease?
In people who later developed Crohn's disease, researchers found increased antibody reactions to herpesviruses. They also had reactions to flagellin, a protein found in bacterial flagella.
These differences were especially noticeable in the participants who were subsequently diagnosed with a complicated course of the disease or a lesion of the ileum. This indicates the possibility of searching early blood samples for information about a future variant of the disease.
At the same time, reactions to bacteria with a protective capsule decreased as they approached the diagnosis. Thus, the changes were not limited to a general strengthening of the immune response: some reactions became more pronounced, others gradually weakened.
The identified links alone do not prove that herpesviruses or certain bacterial proteins cause Crohn's disease. The study shows differences in the reactions of the immune system, and additional work is needed to determine the causes of these changes.
For the authors, one of the most significant results was the association of the early antibody profile with the complicated course of the disease. It suggests that immunological differences between future patient groups exist long before diagnosis.
"Interestingly, complicated Crohn's disease at the time of diagnosis is associated with a special antibody profile years before the first clinical symptoms, and is not just a consequence of the progression of the disease after its diagnosis," said Arnaud Bourgonnier, lead author of the study.
What was discovered before the development of ulcerative colitis
In future patients with ulcerative colitis, scientists have also revealed an increase in reactions to herpesviruses. In addition, reactions to autoantigens, the body's own structures that can become targets of the immune system, increased.
As with Crohn's disease, these changes were accompanied by a decrease in reactions to pathogens with a protective capsule. However, the overall combination of signs was different, which allowed the researchers to consider the diseases separately.
Such results expand the understanding of the period preceding the diagnosis. Changes in blood may reflect a long-term restructuring of immune responses, not just inflammation, which has already become clinically noticeable.
At the same time, the work does not establish a single sequence of disease development for all people. The discovered patterns belong to the studied group, so they have yet to be tested in other populations.
Why is it important to be able to predict complications?
Early detection of risk can be useful not only for finding future cases of the disease. Antibody analysis has the potential to help distinguish between subtypes of the disease and identify patients who need closer monitoring.
In Crohn's disease, researchers saw differences between the future complicated and uncomplicated course long before diagnosis. If these results are confirmed, immune signs can be studied as an additional source of information when choosing patient management tactics.
"Identifying these patterns at such an early stage indicates the potential of antibody analysis to determine risk earlier, differentiate between disease subtypes, and identify patients who may need more intensive care as early as possible," explained Bourgonnier.
However, the work does not yet establish what therapeutic actions should be taken if a similar profile is found in a person without a diagnosis. There are still several verification stages between the identification of a statistical relationship and the decision on treatment.
When will the approach be able to become a diagnostic test?
The authors emphasize that the results so far confirm the fundamental possibility of early detection of immune changes. To create a clinical test, it is necessary to check the identified signs in independent and more diverse groups of people.
The next step should be long-term follow-up studies. They will allow us to assess how reliably the analysis identifies people who will actually develop the disease in the future.
"The next priority is to test these traits in independent, more diverse populations with follow—up," Bourgonier concluded.
In addition, it remains to be determined what additional information the antibody profile provides in comparison with genetic, clinical and other blood parameters. Even a pronounced association with a future diagnosis does not explain how much the new method improves existing risk assessment methods.
A separate task is to translate a large—scale research analysis into a reproducible and accessible test. Checking hundreds of thousands of targets helps to detect patterns, but for practical application it will be necessary to determine which of them are informative enough.
Finally, it must be confirmed that using such a test improves treatment outcomes. An earlier risk signal will gain clinical significance if it helps to choose useful surveillance and medical care tactics in a timely manner. So far, the study provides the basis for this work, but not a ready-made tool for mass examination.
Переведено сервисом «Яндекс Переводчик»